Skip to main content

Thomas P. Frye, D.O.

Contact Information

Phone Numbers

Appointment: (585) 275-2838

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Surgery, Urology


Doctor Thomas Frye currently serves as Associate Professor of Urology and Vice Chair of Clinical Affairs for the Department of Urology at the University of Rochester Medical Center. Dr. Frye, is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of prostate and kidney cancers), and advanced open pelvic and retroperitoneal cancer surgery. He has a special interest and expertise in the management of localized prostate cancer with focal therapy. Dr. Frye has the most comprehensive focal therapy program in upstate New York and offers High Intensity Focused Ultrasound (HIFU), cryotherapy, as well as other ablative technologies. He also participates in national clinical trials evaluating the efficacy of focal therapy for prostate cancer.

Dr. Frye was the valedictorian of his class where he graduated with a Doctor of Osteopathy degree from Midwestern University, Chicago College of Osteopathic Medicine. He went on to complete his urology residency at Southern Illinois University School of Medicine. Dr. Frye was chosen for the prestigious fellowship training in Urologic Oncology within The National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland.

Dr. Frye’s research projects focus on optimizing the screening, diagnosis and treatment of men with prostate cancer. During his fellowship, he worked extensively in refining the use of prostate MRIs in men on active surveillance. Dr. Frye's clinical research interest also includes advanced imaging for prostate cancer as well as focal therapy of prostate cancer.

Dr. Frye is involved in multiple specialty societies including the American Urological Association (AUA), Society of Urologic Oncology (SUO), American Society of Clinical Oncology, and Focal Therapy Society.




    DO | Midwestern University

    Post-doctoral Training & Residency

    07/01/2014 - 06/30/2016
    Fellowship in Urologic Oncology at National Cancer Institute/National Institute of Health

    06/26/2010 - 06/26/2014
    Residency in Urology at Southern Illinois University School Of Medicine

    07/01/2009 - 06/25/2010
    Internship in Urology at Southern Illinois University School Of Medicine

    VIEW ALL expand_more

    Clinical Trials

    Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

    Lead Researcher: Thomas P Frye

    This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.

    View Study Details

    Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR

    Lead Researcher: Thomas P Frye

    The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

    View Study Details


    Journal Articles

    Ghazi A, Melnyk R, Hung AJ, Collins J, Ertefaie A, Saba P, Gurung P, Frye T, Rashid H, Wu G, Mottrie A, Costello T, Dasgupta P, Joseph J. "Multi-institutional validation of a Perfused Robot-Assisted Partial Nephrectomy Procedural Simulation platform utilizing clinically relevant objective metrics of simulators (CROMS)." BJU international.. 2020 Sep 16; Epub 2020 Sep 16.

    Gurung PMS, Frye TP, Rashid HH, Joseph JV, Wu G. "Robot-assisted Synchronous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease: a Stepwise Description of Technique." Urology.. 2020 Jun 17; Epub 2020 Jun 17.

    Witthaus MW, Farooq S, Melnyk R, Campbell T, Saba P, Mathews E, Ezzat B, Ertefaie A, Frye TP, Wu G, Rashid H, Joseph JV, Ghazi A. "Incorporation and validation of clinically relevant performance metrics of simulation (CRPMS) into a novel full-immersion simulation platform for nerve-sparing robot-assisted radical prostatectomy (NS-RARP) utilizing three-dimensional printing and hydrogel casting technology." BJU Int. 2020; .

    Books & Chapters

    Chapter Title: Neuropsychology of Genitourinary Malignancies
    Book Title: Neuropsychology of Cancer and Oncology
    Author List: Frye TP, Miller J, Tarter TH
    Published By: Springer Publishing Company 2012




    Thomas Patrick Frye, D.O., UR Medicine Urology


    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.